2 years ago

BioCorteX Secures $5 Million Seed Funding for Personalized Medicine Platform

  • BioCorteX, a London-based digital medicine company, raised $5 million in seed funding led by Sofinnova Partners and Hoxton Ventures

  • BioCorteX uses a first-principle computer simulation to understand drug-bacteria interactions and improve treatment responses

  • The funding will be used to further develop the company's platform, which creates in-silico simulations to assess and predict an individual's response to treatment based on their microbiome profile.

      • ProblemHealthcare

      "Designing effective treatments by understanding interactions between drugs and bacteria to improve patient responses"

      Solution

      "BioCorteX develops precision medicine solutions using in-silico simulations to predict patient responses to treatments based on their microbiome profiles"

      Covered on